Actavis Group today announced the launch of olanzapine tablets in Germany.
The product is sold via Actavis' third party division, Medis, to other pharmaceutical companies who market the product under their own label. Medis' customers are the first to market a generic version of this product in Germany.
Olanzapine, the generic equivalent of Eli Lilly's Zyprexa, is used in the treatment of schizophrenia and bi-polar disorder. The Actavis product is available as tablets containing 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg.
Annual branded product sales were about EUR3.3 billion globally with the German market accounting for about EUR140 million. Zyprexa, which is Lilly's top selling brand, was the fourth highest selling pharmaceutical product in Europe, and in Germany, in 2006.
Generic olanzapine was developed at Actavis' principal research and development site in Iceland, and is manufactured in Actavis' production plant in Malta for the German market.
More
1 comment:
While I am not exactly on cafe-pharma's side, I don't agree with the statement; “outlets for people who don't have the courage to speak out with their ideas” for improving their roles and the performance of their companies". They don't have courage to speak up because they have seen so many of their peers reprimanded for doing so. And if when they do speak up, are their vioces heard? No, they are shut up and pushed aside.
Post a Comment